The short answer
Efficacy is what a treatment achieves under trial conditions with selected participants and monitored adherence. Effectiveness is what it achieves in routine care. The second is reliably smaller, and the reasons are structural rather than mysterious.
Key facts
- Efficacy
- Trial conditions, selected participants
- Effectiveness
- Routine care, everyone
- Direction
- Effectiveness is reliably lower
- Main causes
- Selection, monitoring, persistence
- Formalised by
- Efficacy vs treatment-policy estimand
- Measured by
- Cohort studies, target trial emulation
Selection is the first cause
Trials exclude people. Those with competing conditions, on interfering medications, unlikely to attend visits, or unable to consent are screened out. The resulting population is healthier and more able to comply than the population who will eventually receive the drug, and the trial result belongs to the group that was studied.
Monitoring is the second
Trial participants are seen regularly, reminded, and have adverse effects managed promptly by people whose job is to keep them in the study. That support is itself an intervention. Removing it does not merely remove convenience; it removes a mechanism that was helping produce the result.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Persistence is the third and largest
The most efficacious treatment achieves nothing in someone who has stopped taking it. Where real-world persistence is substantially lower than trial completion, the population-level effect falls proportionately, and for a chronic condition where stopping reverses the benefit, this dominates the other causes.
How the gap is measured
Observational data analysed carefully, which is where target trial emulation earns its place. It applies trial-like design discipline to routine records, producing an estimate of what happens in practice while removing the analytical biases that would otherwise make such comparisons uninterpretable.
Why the gap is not evidence of a bad trial
A randomised trial is designed to establish whether a drug can work, under conditions favourable enough to detect an effect if one exists. That is a necessary first question, and answering it well requires exactly the control that limits generalisability. Efficacy and effectiveness are two questions, and it is reasonable to answer them in that order.
How to read any headline figure
Ask which question it answers. A 20% reduction from a randomised trial describes selected participants under monitoring, on the efficacy estimand, among those who continued. Every one of those qualifiers moves the number, and a figure travelling without them is describing a situation almost nobody is in.
Quick reference
| Efficacy | Effectiveness | |
|---|---|---|
| Population | Selected | Everyone treated |
| Support | Trial monitoring | Routine care |
| Adherence | High, encouraged | Variable |
| Typical source | Randomised trial | Cohort, emulation |
Frequently asked questions
Why is effectiveness lower than efficacy?
Selection, trial monitoring and real-world persistence. The first two make trial populations perform better; the third removes benefit entirely for those who stop.
Does the gap mean the trial was flawed?
No. A trial establishes whether a drug can work, which requires control that necessarily limits generalisability. They are two questions asked in order.
How is effectiveness measured?
Observational data analysed with trial-like discipline, with target trial emulation being the method built for exactly this.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDziewierz A et al., Adherence and Persistence with GLP-1-Based Therapies. Nutrients 2026 (PMID 42280404)pubmed.ncbi.nlm.nih.gov
- PubMedMody R et al. Curr Med Res Opin 2018 (PMID 29271258)pubmed.ncbi.nlm.nih.gov
- PubMedLin YM et al., Effectiveness of tirzepatide in HFpEF using target trial emulation. Nat Commun 2025 (PMID 40368924)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Why Weight Loss Can Restore OvulationObesity and insulin resistance disrupt ovulation, particularly in PCOS. Reversing them can restore fertility - which is a documented effect, not a rumour.
- Restored Fertility and Reduced Contraceptive AbsorptionOne effect makes conception more likely; another can reduce contraceptive protection. They act in the same population, and neither announces itself.
- When the Reason for Treatment Causes the OutcomePeople given a drug differ from those not given it - by the condition that prompted it. A 2026 Danish cohort shows the problem unusually clearly.
- Why Age Changes the CalculationThe same weight reduction carries different consequences at 75 than at 45. Lean mass, bone and nutritional intake all sit differently.
- Where a Peptide Stops Being a DrugFDA treats 40 residues or fewer as a peptide - a drug. Longer is a protein, a biologic. That single number governs how generics reach the market.